Delveinsight

JANUARY 12, 2021

Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by binding to them, ultimately leading to cell death in tumor cells. The companies believe that their candidate in its original IgG format has shown potent neutralization activity in in vitro assays and in an in vivo animal model.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

Drug Discovery World

FEBRUARY 9, 2024

DDW recently hosted a webinar ‘Discover how iPSC derived cells can be used to support the development of drug and gene therapies’, supported by DefiniGEN. Chris explained that DefiniGEN is a liver cell company focussed on hepatocytes, particularly supporting the drug development industry in producing liver therapies.

Gene Therapy 52

Gene Therapy Gene Development Drugs 52

Drug Discovery World

SEPTEMBER 19, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling.

Gene Therapy 52

Gene Therapy Gene Development Protein 52

Drug Discovery World

SEPTEMBER 12, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling.

Gene Therapy 52

Gene Therapy Gene Development Drugs 52

Drug Discovery World

AUGUST 25, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality. However, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling.

Gene Therapy 52

Gene Therapy Gene Development Genotype 52

Drug Discovery World

OCTOBER 13, 2022

Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

SEPTEMBER 5, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling.

Development 59

Development Drugs Protein Genotype 59

Drug Discovery World

SEPTEMBER 26, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling.

Development 52

Development Drugs Protein Genotype 52

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

Vaccination 52

Vaccination Vaccine DNA Protein 52

pharmaphorum

JANUARY 16, 2023

Last year, IQVIA predicted that 2022 would be the crunch year for Alzheimer’s therapies: it is with a sense of déjà vu that the exact same prediction is contemplated for 2023. This is linked to wider questions about the role damaged proteins and their build up plays in ageing across different tissues and organs.

Gene Therapy 98

Gene Therapy In-Vitro Gene Medicine 98

Pharmaceutical Technology

AUGUST 26, 2008

” According to Chris Reilly, global vice president of discovery, strategy and performance for AstraZeneca, it is now recognised that biotechnology unquestionably offers important benefits for the pharmaceuticals industry by presenting alternatives to other therapies. “Biotechnology has exploded across the industry. .

Antibody 130

Antibody Licensing Licensing Production 130

Delveinsight

JANUARY 18, 2021

Usually, only a single copy of the gene is required that too from the mother, however, in cases of AS, either the child does not get any copy, or the child receives two copies – each from mother and father. GeneTx and Ultragenyx are co-developing the therapy.

Marketing 52

Marketing Gene Drugs Protein 52

Drug Discovery World

APRIL 12, 2023

Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

JANUARY 20, 2023

Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

OCTOBER 13, 2022

One aspect that makes mRNA technology popular with drug developers is that its proteins can be easily edited. One aspect that makes mRNA technology popular with drug developers is that its proteins can be easily edited. Why mRNA has potential . mRNA presents versatility plus flexibility to target a broader range of diseases. .

Drugs 52

Drugs Manufacturing Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 27, 2023

which removes the mandatory requirement for animal testing in the development of drugs for toxicity where enhanced performance is proven using in vitro alternatives. The technology offers features for cell and gene therapy developers and manufacturers, such as end stage deployment at the clinic or hospital.

Drugs 52

Drugs Life Science Protein Scientist 52

Drug Discovery World

JANUARY 23, 2023

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. Adult fibroblasts were cultured in a cocktail of transcription factors to reactivate embryonic gene expression patterns 2.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

FEBRUARY 22, 2024

According to Medicine Discovery Catapult, these include: “Navigating the complexity of the CNS; understanding the disease pathology, and accessing predictable in vitro and in vivo cell models 2 ”. Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In In 2019, dementia accounted for 1.8

Drugs 59

Drugs Gene Clinical Trials Clinical Trials 59